402 related articles for article (PubMed ID: 32700072)
21. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Bazinet A; Assouline S
Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
[No Abstract] [Full Text] [Related]
22. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
23. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
[TBL] [Abstract][Full Text] [Related]
24. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
de Leeuw DC; Ossenkoppele GJ; Janssen JJWM
Curr Oncol Rep; 2022 Nov; 24(11):1387-1400. PubMed ID: 35653050
[TBL] [Abstract][Full Text] [Related]
25. Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Janus SE; Heisler AC; Al Jammal M; Chahine N; Chami T; Hajjari J; Mously H; Badhwar A; Arora S; Al-Juhaishi T; Al-Kindi SG; Hoit BD
Curr Probl Cardiol; 2022 Nov; 47(11):101345. PubMed ID: 35948197
[TBL] [Abstract][Full Text] [Related]
26. The role of targeted therapy in the management of patients with AML.
Perl AE
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):54-65. PubMed ID: 29222237
[TBL] [Abstract][Full Text] [Related]
27. A personalized approach to acute myeloid leukemia therapy: current options.
Illangeswaran RSS; Das S; Paul DZ; Mathews V; Balasubramanian P
Pharmgenomics Pers Med; 2019; 12():167-179. PubMed ID: 31447578
[TBL] [Abstract][Full Text] [Related]
28. The clinical impact of the molecular landscape of acute myeloid leukemia.
Kayser S; Levis MJ
Haematologica; 2023 Feb; 108(2):308-320. PubMed ID: 36722402
[TBL] [Abstract][Full Text] [Related]
29. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
30. The role of targeted therapy in the management of patients with AML.
Perl AE
Blood Adv; 2017 Nov; 1(24):2281-2294. PubMed ID: 29296877
[TBL] [Abstract][Full Text] [Related]
31. The beginning of a new therapeutic era in acute myeloid leukemia.
Récher C
EJHaem; 2021 Nov; 2(4):823-833. PubMed ID: 35845213
[TBL] [Abstract][Full Text] [Related]
32. Updates on targeted therapies for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
[TBL] [Abstract][Full Text] [Related]
33. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
Andreozzi F; Massaro F; Wittnebel S; Spilleboudt C; Lewalle P; Salaroli A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409248
[TBL] [Abstract][Full Text] [Related]
34. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Estey E; Karp JE; Emadi A; Othus M; Gale RP
Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
[TBL] [Abstract][Full Text] [Related]
35. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
36. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer G; Bullinger L; Garcia-Vidal C; Herbrecht R; Maertens J; Menna P; Pagano L; Thiebaut-Bertrand A; Calandra T
Leukemia; 2022 May; 36(5):1215-1226. PubMed ID: 35368047
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
39. AML: New Drugs but New Challenges.
Burnett A; Stone R
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
Gottardi M; Simonetti G; Sperotto A; Nappi D; Ghelli Luserna di Rorà A; Padella A; Norata M; Giannini MB; Musuraca G; Lanza F; Cerchione C; Martinelli G
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
